Quotient Sciences is a Business Reporter client
With a global client base ranging from emerging biotechnology organisations to Fortune 500 pharmaceutical companies, Quotient Sciences offers a compelling solution for innovators seeking speed, efficiency and quality in bringing new therapies to patients.
For 35 years and with operations in the UK and the US, Quotient Sciences has worked on hundreds of products used to treat conditions ranging from cancer to rare diseases. As a contract research, development and manufacturing organisation (CRDMO), the company specialises in the early clinical research and development of drug products for clinical trials and prescription medicines.
Shared success in a drug’s journey
Bringing a molecule to market is a complex, costly and high-risk journey. A drug must go through clinical research and approval by regulatory agencies, such as the United Kingdom Medicines and Healthcare products Regulatory Agency (UK MHRA) or United States Food and Drug Administration (US FDA).
A new drug is first tested in humans during Phase I trials; these address safety and dose, typically in healthy volun
Continue Reading on The Independent
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.